Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:Active Not Recruiting
NCT03875573Phase 2Updated Dec 20, 2024
Sponsor: Jules Bordet Institute
Luminal B
Belgium, France
Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung CancerTerminated
NCT04364048Phase 2Updated Dec 20, 2024
Sponsor: Rachel Sanborn
Lung Cancer · Non-small Cell Carcinoma
United States
Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBCActive Not Recruiting
NCT03616886Phase 1, Phase 2Updated Dec 19, 2024
Sponsor: Jules Bordet Institute
Triple Negative Breast Cancer
Belgium, France
A Real-World Assessment of the Demographic, Clinical Characteristics and Outcomes of a Brazilian Cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer Receiving Durvalumab Combined With Platinum-Etoposide in (ES-SCLC) in BrazilActive Not Recruiting
NCT06008353N/AUpdated Dec 19, 2024
Sponsor: AstraZeneca
Extensive-stage Small-cell Lung Cancer
Brazil
Opening the "Black Box" on Tezepelumab's Effect on Chronic Rhinosinusitis With Severe AsthmaNot Yet Recruiting
NCT06740045Phase 3Updated Dec 18, 2024
Sponsor: Dr. Andrew Thamboo, MD
Asthma · Chronic Rhinosinusitis With Nasal Polyps
Japanese Phase I Study of AZD2014 in Advanced Solid MalignanciesCompleted
NCT02398747Phase 1Updated Dec 17, 2024
Sponsor: AstraZeneca
Advanced Solid Malignancies
Japan
AZD9833 China PK StudyCompleted
NCT04818632Phase 1Updated Dec 17, 2024
Sponsor: AstraZeneca
ER+, HER2-, Metastatic Breast Cancer
China
REVEAL-CKD: Prevalence and Consequences of Undiagnosed Chronic Kidney DiseaseCompleted
NCT04847531N/AUpdated Dec 16, 2024
Sponsor: AstraZeneca
Chronic Kidney Disease
United States, Australia, Brazil, Canada, China +6 more
Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124Completed
NCT05459688Phase 2Updated Dec 16, 2024
Sponsor: AstraZeneca
Hypertension
United States
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy ParticipantsCompleted
NCT06122714Phase 1Updated Dec 13, 2024
Sponsor: AstraZeneca
Healthy Participants
United States
A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186Terminated
NCT05694741Phase 1Updated Dec 13, 2024
Sponsor: AstraZeneca
Type 2 Diabetes
United States
Exacerbations Among Patients Receiving Breztri (EROS Study)Completed
NCT06514144N/AUpdated Dec 13, 2024
Sponsor: AstraZeneca
Pulmonary Disease · Chronic Obstructive · Retrospective Studies
United States
FAsenra Safety Trial in IndiaCompleted
NCT05384938Phase 4Updated Dec 11, 2024
Sponsor: AstraZeneca
In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India
India
A Multicenter, Prospective, Non-interventional Cohort Study to Evaluate the Safety and Treatment Pattern of Sodium Zirconium Cyclosilicate for Hyperkalaemia Management in Real World Practice in ChinaCompleted
NCT05271266N/AUpdated Dec 11, 2024
Sponsor: AstraZeneca
Hyperkalaemia
China
Assessing DNA Changes in High Risk Prostate Cancer to Determine PrognosisWithdrawn
NCT01350180N/AUpdated Dec 10, 2024
Sponsor: Dr. Tamim Niazi
Prostate Cancer
Canada
Change in Patient-Reported Outcomes in Severe Eosinophilic Asthma Patients Treated With Benralizumab Under Real-life ConditionsCompleted
NCT04184284N/AUpdated Dec 9, 2024
Sponsor: AstraZeneca
Asthma
Germany
Immunotherapy Combined With Y-90 and SBRT for Colorectal Liver MetastasesWithdrawn
NCT03802747Phase 1Updated Dec 9, 2024
Sponsor: University of Colorado, Denver
Colorectal Cancer
Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint InhibitionWithdrawn
NCT04064190Phase 2Updated Dec 9, 2024
Sponsor: MedPacto, Inc.
Urothelial Carcinoma Recurrent · Advanced Urothelial Carcinoma
United States
Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line ImmunotherapyActive Not Recruiting
NCT05000710Phase 2Updated Dec 5, 2024
Sponsor: Sheba Medical Center
Metastatic or Locally Advanced NSCLC
Israel
A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast CancerRecruiting
NCT04985266Phase 2Updated Dec 5, 2024
Sponsor: Royal Marsden NHS Foundation Trust
ER+ Breast Cancer · HER2-negative Breast Cancer
France, United Kingdom
Pharmacokinetics of Mitiperstat in Participants With Hepatic ImpairmentCompleted
NCT05751759Phase 1Updated Dec 5, 2024
Sponsor: AstraZeneca
Hepatic Impairment
United States
Real World Evidence of Long-term Safety and Efficacy in Patients Treated With Durvalumab After Concurrent Chemoradiation for Unresectable Stage III NSCLCCompleted
NCT03995875N/AUpdated Dec 5, 2024
Sponsor: AstraZeneca
Carcinoma, Non-Small-Cell Lung
Japan
Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation ApproachCompleted
NCT03702179Phase 2Updated Dec 5, 2024
Sponsor: Spanish Oncology Genito-Urinary Group
Invasive Bladder Cancer
Spain
Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.Completed
NCT03838744Phase 2Updated Dec 4, 2024
Sponsor: Italian Sarcoma Group
Advanced Soft Tissue Sarcoma
Italy
Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial FibrillationCompleted
NCT04792190Phase 4Updated Dec 4, 2024
Sponsor: University of Rochester
Atrial Fibrillation
United States

Previous page Next page